Walleye Capital’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-900
Closed -$11.6K 4966
2025
Q3
$11.6K Hold
900
﹤0.01% 4269
2025
Q2
$16K Buy
+900
New +$15.7K ﹤0.01% 4266
2025
Q1
Sell
-2,500
Closed -$74.5K 4852
2024
Q4
$74.5K Buy
2,500
+1,300
+108% +$27.5K ﹤0.01% 4243
2024
Q3
$18.8K Sell
1,200
-900
-43% -$16.3K ﹤0.01% 4824
2024
Q2
$36K Sell
2,100
-1,100
-34% -$19.3K ﹤0.01% 5016
2024
Q1
$50K Sell
3,200
-2,400
-43% -$35.3K ﹤0.01% 4677
2023
Q4
$83.6K Buy
5,600
+1,300
+30% +$17.4K ﹤0.01% 4125
2023
Q3
$69.4K Buy
4,300
+4,000
+1,333% +$115K ﹤0.01% 4094
2023
Q2
$12.4K Sell
300
-8,500
-97% -$528K ﹤0.01% 3879
2023
Q1
$529K Buy
8,800
+7,800
+780% +$623K 0.01% 1661
2022
Q4
$73.3K Sell
1,000
-4,200
-81% -$316K ﹤0.01% 2441
2022
Q3
$395K Buy
+5,200
New +$406K 0.01% 1629
2019
Q4
Sell
-4,500
Closed -$337K 2114
2019
Q3
$337K Sell
4,500
-100
-2% -$8K 0.02% 931
2019
Q2
$291K Sell
4,600
-14,400
-76% -$730K 0.03% 749
2019
Q1
$915K Buy
+19,000
New +$914K 0.15% 192

Other funds holding NVCR

Walleye Capital's NVCR Position: Q1 2026 in Review

Walleye Capital sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 11,676 shares — an estimated $151K sold.

Walleye Capital first reported a position in NVCR in Q1 2019 and held it in 16 quarters. The position peaked at $2.8M in Q3 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Walleye Capital reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 11,676 NovoCure shares in Q1 2026, an estimated $151K.
  • Walleye Capital first reported a position in NovoCure in Q1 2019 and held it in 16 quarters.
  • Walleye Capital's NovoCure position peaked at $2.8M in Q3 2025.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.